Objective: In this study, it was aimed to examine the prognostic significance of copeptin in patients with community-acquired pneumonia (CAP) who were admitted to the emergency department.

Materials and Methods: Vital signs, symptoms, examination findings, background information, pneumonia severity scores, laboratory results, and radiological imaging results of 61 patients diagnosed with CAP who were admitted to the emergency department were recorded. Serum copeptin levels of the patients were measured at the time of admission.

Results: 32 (thirtytwo) (52.5%) of 61 patients in the study were male. The median age of the patients was 73 (31-91). 19 out of 61 patients died during the 30-day follow-up period. The copeptin levels of the patients who died were significantly higher than those who survived (p<0.05). When the patients were grouped according to pneumonia severity scores, no significant difference was observed between biomarkers. In the ROC analysis of models that were created with biomarkers and pneumonia severity scores, the strongest indicator was Copeptin + C-reactive protein + procalcitonin (AUC 0.747).

Conclusion: As a result, plasma copeptin level can be used in community-acquired pneumonia to estimate severity and mortality. Multiple use of biomarkers and/or use with pneumonia risk scores is superior to their singular use in determining disease prognosis and mortality.